Almirall has acquired the rights to Veltin and Altabax, from Stiefel, a GSK company, in exchange for distribution rights to Toctino and an undisclosed cash payment
Almirall acquires rights to two dermatology drugs
The two drugs which Almirall has acquired are dermatology drugs – Altabax is a topical treatment for Impetigo, a highly contagious bacteria infection in children and Veltin is a prescription antibiotic indicated for the topical treatment of acne.
Both Veltin and Altabax will be commercialised through Almirall’s US affiliate, Aqua Pharmaceuticals.
Eduardo Sanchiz, Almirall chief executive officer, said: “Considering the significant expertise of Aqua Pharmaceuticals in the Dermatology field, we are convinced they will be in a good position to maximise the potential of Veltin and Altabax.
“Both medicines are a perfect fit with our current portfolio, are aligned with our global strategy and strengthen our position in the US, which is the world’s largest Dermatology market”.
As part of the agreement Almirall exchanged Veltin and Altabax for its distribution rights to Toctino.
In June 2010, Almirall and Basilea Pharmaceutica signed a distribution agreement for Toctino, granting Almirall commercialisation rights in selected European markets and Mexico.
Stiefel acquired worldwide rights to Toctino in June 2012 from Basilea and through the new agreement with Almirall now has consolidated rights to Toctino in Europe.